Helicobacter Pylori Diagnostics Market Increasing the Growth Worldwide: Industry Analysis, Growth, Drivers, Limitations, Regions, Forecast 2026
Helicobacter pylori is a bacteria that resides on the lining of human stomach. Helicobacter produces chemicals, causing inflammation of stomach, which progresses to peptic ulcer or gastric cancer. Helicobacter pylori infection can be detected by simple and accurate tests such as breath test, blood tests, endoscopy, and stool tests. Based on the sample preparation, helicobacter pylori diagnostic assays are segmented into invasive methods, which includes immunoassay, rapid urease test, and histology, and Non-invasive methods, which includes stool antigen assay, serology test and urease breath test. Increasing infection prevalence in emerging economies and high demand for point-of-care testing are major factors driving growth of Helicobacter pylori diagnostics market.
Get Exclusive Sample Report at: https://www.coherentmarketinsights.com/insight/request-sample/1874
Market players are investing in developing point-of-care and accurate diagnostics products to gain competitive advantage. For instance, in 2017, Exaleza Bioscience launched Automated BreathID Hp Lab Urea Breath Testing System for detection of Helicobacter pylori. The system is point-of-care, with 99% sensitivity and specificity for H. pylori. Furthermore, companies are focusing enhancing product portfolio through inorganic growth strategies. For instance, Abbott Laboratories acquired Alere Inc., the global leader in point of care diagnostics, in order to expand its product portfolio and geographic presence. With this acquisition, Abbott could access to Alere’s rapid diagnostics segment, which includes H. pylori detection kits. However, limitations associated with the currently available diagnostic assays are expected to restrain the Helicobacter pylori diagnostics market. For instance, urea breath test and stool antigen test cannot be used in patients undergoing proton pump inhibitors treatment.
Increasing prevalence of helicobacter pylori in emerging economies is propelling the Helicobacter pylori diagnostics market growth
Prevalence of helicobacter pylori is declining in developed countries, whereas its prevalence in emerging economies is increasing. For instance, according to the Faculty of Medicine of The Chinese University of Hong Kong (CUHK), 2017, around 4.4 billion people worldwide are infected with Helicobacter pylori (H. pylori). Furthermore, same source suggested that prevalence in Africa is up to 80%, which is the highest globally, while in Asia, over 50% of the population was infected with H. pylori. Moreover, according to the International Agency for Research on Cancer report 2014, in 2012, around 952,000 new gastric cancer cases occurred globally and around 734,000 gastric cancers were estimated to occur due to H. pylori infection. Such high prevalence of Helicobacter pylori in Africa and Asia is expected to fuel the regional helicobacter market growth.
Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1874
Inorganic strategies by key players is fuelling growth of the Helicobacter pylori diagnostics market
Key players involved in the global Helicobacter pylori diagnostics market include Thermo Fisher Scientific, Inc., Bio-Rad Laboratories Inc., Diasorin S.P.A., Quidel Corporation, F. Hoffmann-La Roche Ltd.(Ventana Medical Systems, Inc.), Meridian Bioscience, Inc., Exalenz Bioscience Ltd., Abbott Laboratories, Cardinal Health, Inc., and Halyard Health, Inc.